Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Peroxide SCHEMBL8609521 | 0.81 | ACP3 (0.50) | ACP3CYP2D6LMNASRCPOLB | |
| SCHEMBL31315617 | 0.81 | ACP3 (0.50) | ACP3CYP2D6LMNASRCPOLB | |
| SCHEMBL5053055 | 0.80 | FOLH1 (0.55) | — | |
| SCHEMBL12858790 | 0.78 | CYP2D6 (0.65) | CYP2D6ALDH1A1CYP1A2TSHRCYP2C19 | |
| SCHEMBL2171241 | 0.77 | ACP3 (0.44) | ACP3CYP2D6SRC | |
| SCHEMBL3817936 | 0.77 | ACP3 (0.63) | ACP3LMNASRCPOLB | |
| SCHEMBL340009 | 0.76 | APAF1 (0.44) | ACP3LMNA | |
| SCHEMBL5051130 | 0.76 | ACP3 (0.42) | ACP3ALDH1A1CYP2C19LMNA | |
| SCHEMBL2170906 | 0.75 | TSHR (0.43) | ACP3TSHRNPSR1 | |
| SCHEMBL5054260 | 0.74 | GGH (0.60) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097753-B2 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-01-17 | — | — | US | disclosed |
| EP-1832594-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT FINANCE BVI LTD (VG) | 2011-05-18 | — | — | EP | disclosed |
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832594-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | PAH, ALKBH3, FTO | ACP3 3182/4885CYP2D6 961/4885ALDH1A1 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.